A clinical trial to study the effect of intra operative use of platelet rich plasma on the outcome of melanocyte transplant surgery
Not Applicable
- Conditions
- Health Condition 1: null- Stable Vitiligo
- Registration Number
- CTRI/2018/03/012591
- Lead Sponsor
- Intitutional research committee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with stable Vitilgo with no increase in size of lesion for past 06 months
Exclusion Criteria
1) Unstable vitiligo (New lesion or extension of pre-existing lesion)
2) Vitiligo stabilized on systemic medical therapy
3) Evidence or history of keloid/hypertrophic scars.
4) Patients with chronic auto immune and infectious diseases e.g. DM, Thyroid disease, HTN, Hep B,C,HIV etc.
5) Patients with bleeding disorders or on medications affecting platelet function e.g. Ecosprin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary measure of efficacy of treatment is the percentage of repigmentation 06(Six) months after surgery which will be assessed by two independent investigators and the lesser value will be used for assessment of results. Pigmentation will be graded as excellent(90%), very good (76â??90%), goo (51â??75%), fair (26â??50%), and poor (25%).Timepoint: One, three and six months
- Secondary Outcome Measures
Name Time Method Improvement in Dermatology Life Quality Index (DLQI) score (assessed before and 6 months after surgery) and patient satisfaction assessed by asking patients to complete a patient satisfaction questionnaire. <br/ ><br>Additionally, adverse events will be noted as a safety outcome measure. <br/ ><br>Timepoint: Before and 6 months after surgery